AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
2024-09-16 (expresshealthcare.in)
ICMR signs agreements for first-in-human clinical trials of four new molecules –
ICMR partners with industry leaders for trials on molecules targeting multiple myeloma, Zika, influenza, and chronic lymphocytic leukaemia
Read more
2022-12-16 (financialexpress.com)
Dr. Reddy's subsidiary Aurigene Oncology halts clinical trials of its psoriasis drug in US - Healthcare News | The Financial Express
The company announced that it will be closing the clinical development of AUR101 in psoriasis.
Read more
(cnbctv18.com)
Dr Reddy's unit achieves trial breakthrough: Positive results for blood cancer treatment - CNBC TV18
"The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India," said Murali Ramachandra, CEO of Aurigene Oncology. "We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma."
Read more